Relapse After Second-Line Therapy in Follicular Lymphoma

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed follicular lymphoma.

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no added benefit over induction alone.

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after phase 3 trial enrollment milestone.

Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.